Zacks Research cut shares of Novozymes A/S (OTCMKTS:NVZMY – Free Report) from a hold rating to a strong sell rating in a research note issued to investors on Monday morning,Zacks.com reports.
Separately, Rothschild & Co Redburn raised Novozymes A/S to a “strong-buy” rating in a research report on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.
View Our Latest Stock Analysis on Novozymes A/S
Novozymes A/S Trading Down 0.0%
Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.51 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.31). Novozymes A/S had a net margin of 13.96% and a return on equity of 6.37%. On average, research analysts predict that Novozymes A/S will post 2.42 EPS for the current fiscal year.
About Novozymes A/S
Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.
The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).
Further Reading
Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.
